secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001708599-25-000002
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics files investor presentation with preliminary 2024 data; no specific figures disclosed
--------------------------------------------------------------------------------

- Exhibit 99.1 provides a presentation highlighting Serina's POZ Platform for drug delivery.
- Filing states preliminary unaudited financial info as of Dec 31, 2024, but these figures are not included in the filing text or exhibit excerpt.
- Presentation mentions RNA delivery and improved ADCs, but no revenue, cash, or other concrete financial metrics are given.
- The company is an emerging growth company; audit of full-year 2024 results is ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000002/0001708599-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000002/ser-20250106.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer